Innovative Therapy, Monoclonal Antibodies and Beyond.

摘要: The seventh Edition of "Innovative Therapy, Monoclonal Antibodies and Beyond" Meeting took place in Milan, Italy, on January 27, 2017. two sessions the meeting were focused on: 1) Preclinical assays novel biotargets; 2) monoclonal antibodies, cell therapies targeted molecules. Between these sessions, a lecture entitled "HLA-antigens modulation response to immune checkpoint inhibitor immunotherapy" was also presented. Despite impressive successes cancer immunotherapy recent years, based interventions occurs only minority patients (∼20%). Several basic translational mechanisms resistance blockers (ICBs) discussed during meeting: 1. impact tumor microenvironment activity system; 2. strategies inhibit cross-talk between extracellular matrix myeloid-derived suppressor cells (MDSC) preclinical setting; 3. microRNA expression as biomarker target therapy non-small lung (NSCLC); 4. significance complement activation pathways inhibitors; 5. immunosuppressive microbiota by inducing IL-17 producing cells; 6. HLA antigens possible markers ICB therapy. In order overcome deficiency active anti-tumor T cells, several clinically applicable combination discussed: enhance anticancer effects immunogenic death inducing-chemotherapy; use CAR T-cells solid tumors; involving oncolytic viruses ICBs; combinations new ICBs with anti-PD-1/CTLA-4 therapy; melanoma. Overall, this conference emphasized many that are being investigated improve overall patient immunotherapy. Optimization biomarkers accurately select who will respond immunotherapy, coupled long term survival remain critical challenges immuno-oncology field.